ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Liraglutide

Also written as “liraglutide”, “insulin degludec/liraglutide” and “Insulin degludec/liraglutide”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Diabetes Mellitus, Type 1 · Osteoarthritis, Knee, led by 10 companies.

Drug pageLiraglutide: every studyMany companies study it; this page follows only the 109 they lead. All 336 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 22, 2013109 company-led studies, 5 open or runningNext primary completion: Dec 13, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only972 open or runningphase 4since Jul 22, 2013Sep 8, 2005Dec 13, 2026phase 1 · NCT07225816
4Moving Biotechits history only20 open or runningphase 2since Sep 24, 2025Jun 7, 2022none ahead
Eli Lilly20 open or runningphase 4since Feb 24, 2014May 31, 2013none ahead
Tonghua Dongbao Pharmaceuticalits history only22 open or runningphase 3since Aug 14, 2024Jun 2, 2024none ahead
Biolingusits history only11 open or runningphase 2since Feb 16, 2022Feb 16, 2022none ahead
Cinnagenits history only10 open or runningphase 3since Jan 29, 2018Jan 29, 2018none ahead
ikfe-CROits history only10 open or runningphase 4since Sep 17, 2010Sep 17, 2010none ahead
Merckits history only10 open or runningphase 1since Jun 13, 2011Jun 13, 2011none ahead
Pfizerits history only10 open or runningphase 1since Feb 1, 2017Feb 1, 2017none ahead
Sino Biopharmaceuticalits history only10 open or runningphase 1since Aug 24, 2021Aug 24, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2013First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT01870297 · 72 enrolled · United States
  2. Feb 24, 2014Phase 4 study in Diabetes Mellitus, Type 2NCT02072096 · 192 enrolled · United States, Austria, Germany and more

TargetBeta

GLP1R →read by rule
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule

Other programs on GLP1R

ProgramCompanyFurthest phaseStudies
SemaglutideruleNovo Nordiskphase 4170
TirzepatideruleEli Lillyphase 472
dulaglutideruleEli Lillyphase 447
orforglipronruleEli Lillyphase 350
zenagamtideNovo Nordiskphase 336
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
mazdutideruleInnovent Biologicsphase 327
bofanglutideruleGan & Lee Pharmaceuticalsphase 325
berobenatidePfizerphase 323
brenipatideEli Lillyphase 319
SafiglipronJiangsu HengRui Medicinephase 319

Studies

All 2 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02072096Diabetes Mellitus, Type 2 · United States, Austria, Germany and more4TerminatedOct 2015192
NCT01870297Diabetes Mellitus, Type 2 · United States1CompletedDec 201472

How it is read

Names in the registry

  • “liraglutide”, 114 entries
  • “insulin degludec/liraglutide”, 11 entries
  • “Liraglutide”, 10 entries
  • “Insulin degludec/liraglutide”, 3 entries
  • “NN9924 (oral)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.